Borlaug, Barry A.

Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction

Pandey, A., Shah, S. J., Butler, J., Kellogg, D. L., Lewis, G. D., Forman, D. E., Mentz, R. J., Borlaug, B. A., Simon, M. A., Chirinos, J. A., et al. (2021) · Journal of the American College of Cardiology

Cardiovascular and exercise physiologyHeart Failure Treatment and Management

Cited by 184

Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial

Borlaug, B. A., Zile, M. R., Kramer, C. M., Baum, S. J., Hurt, K., Litwin, S. E., Murakami, M., Ou, Y., Upadhyay, N., & Packer, M. (2025) · Nature Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 166

Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study

Reddy, Y. N. V., Lewis, G. D., Shah, S. J., Obokata, M., Abou-Ezzedine, O. F., Fudim, M., Sun, J.-L., Chakraborty, H., McNulty, S., LeWinter, M. M., et al. (2019) · Mayo Clinic Proceedings

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 141

Beyond Low-Density Lipoprotein Cholesterol

Mudd, J. O., Borlaug, B. A., Johnston, P. V., Kral, B. G., Rouf, R., Blumenthal, R. S., & Kwiterovich, P. O. (2007) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 136

Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction

Sorimachi, H., Burkhoff, D., Verbrugge, F. H., Omote, K., Obokata, M., Reddy, Y. N. V., Takahashi, N., Sunagawa, K., & Borlaug, B. A. (2021) · European Journal of Heart Failure

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 124

Artificial Intelligence-Enabled ECG for Left Ventricular Diastolic Function and Filling Pressure

Lee, E., Ito, S., Miranda, W. R., Lopez-Jimenez, F., Kane, G. C., Asirvatham, S. J., Noseworthy, P. A., Friedman, P. A., Carter, R. E., Borlaug, B. A., et al. (2024) · npj Digital Medicine

ECG Monitoring and AnalysisCardiovascular Function and Risk Factors

Cited by 106

Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial

Kosiborod, M. N., Verma, S., Borlaug, B. A., Butler, J., Davies, M. J., Jon Jensen, T., Rasmussen, S., Erlang Marstrand, P., Petrie, M. C., Shah, S. J., et al. (2024) · Circulation

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 104

Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype

Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Christensen, L., Davies, M., Hovingh, K. G., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · JACC: Heart Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 97

Semaglutide and NT-proBNP in Obesity-Related HFpEF

Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Shah, S. J., Verma, S., Jensen, T. J., Einfeldt, M. N., Liisberg, K., et al. (2024) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 95

Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

Zile, M. R., Borlaug, B. A., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ou, Y., Weerakkody, G. J., Hurt, K. C., Kanu, C., et al. (2025) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 74

Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure With Preserved Ejection Fraction

Reddy, Y. N. V., Obokata, M., Testani, J. M., Felker, G. M., Tang, W. H. W., Abou-Ezzeddine, O. F., Sun, J.-L., Chakrabothy, H., McNulty, S., Shah, S. J., et al. (2020) · Journal of Cardiac Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 51

Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

Packer, M., Zile, M. R., Kramer, C. M., Murakami, M., Ou, Y., & Borlaug, B. A. (2025) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 49

Central and peripheral determinants of exercise capacity in heart failure patients with preserved ejection fraction

Wolsk, E., Kaye, D., Komtebedde, J., Shah, S. J., Borlaug, B. A., Burkhoff, D., Kitzman, D. W., Lam, C. S. P., van Veldhuisen, D. J., Ponikowski, P., et al. (2019) · JACC Heart Failure

Cardiovascular and exercise physiologyHeart Failure Treatment and Management

Cited by 43

Impact of obesity on volume status in patients with ambulatory chronic heart failure

Miller, W. L., & Borlaug, B. A. (2020) · Journal of Cardiac Failure

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 42